
Daily Briefing: Vaccine-Carrying Mosquitoes Could Inoculate Bats Against Rabies
Researchers have engineered Aedes aegypti mosquitoes to carry vaccine antigens in their saliva, successfully inoculating bats against rabies and Nipah viruses in laboratory experiments. The mosquitoes were fed vaccine‑laden blood, then transmitted the immunogen when they fed on or were eaten by bats, inducing protective immunity. The team proposes this paratransgenic approach as a tool to curb bat‑to‑human spillover of deadly zoonoses. However, experts caution that ecological complexity and field efficacy remain unresolved.
DNA Origami Vaccine Rivals mRNA Shots While Being Easier to Store and Manufacture
Researchers at Harvard’s Wyss Institute and Dana‑Farber unveiled DoriVac, a DNA origami‑based vaccine platform that delivers antigens and adjuvants on a self‑folding nanostructure. In pre‑clinical mouse studies and a human lymph‑node‑on‑a‑chip model, DoriVac generated antibody and T‑cell responses comparable to...
Researchers Use AI to Develop RNA-Based Synthetic NAND Switch in Living Cells
Researchers at TU Darmstadt have engineered the first RNA‑based synthetic NAND gate by linking two riboswitches that respond to distinct ligands. Using high‑throughput screening combined with a deep‑learning‑driven Bayesian optimization loop, they evaluated only 82 variants to isolate sequences that exhibit...

Startup Vima Adds Parkinson’s to Movement Disorder Scope, Expanding Series A Round to $100M
Vima Therapeutics announced an additional $40 million raise, taking its Series A funding to $100 million. The capital will support parallel Phase 2 trials of its lead candidate VIM0423 in isolated dystonia and Parkinson’s disease, expanding the startup’s focus beyond the rare movement disorder....

Gut‑brain Signaling Fixes Age‑related Memory Loss
Intestinal interoceptive dysfunction drives age-associated cognitive decline "We leverage this pathway to define interventions that enhance memory in aged mice, such as phage targeting of Parabacteroides, GPR84 inhibition and restoration of vagal activity. These findings indicate a key role for interoceptive dysfunction...
Can FDA Tolerate Cancer Risk for Rare Pediatric Disease Gene Therapies?
The FDA placed a clinical hold on Regenxbio’s RGX‑111 and RGX‑121 gene‑therapy trials after a pediatric MPS I patient developed a tumor four years post‑treatment. The case marks the first documented long‑latency cancer linked to an adeno‑associated virus (AAV) vector in...
Science Spotlight: New Ways to Attack Β-Amyloid Plaques in Alzheimer’s
Two pre‑clinical studies propose active clearance of β‑amyloid as a new Alzheimer’s strategy. Researchers at Washington University engineered astrocytes with chimeric antigen receptors (CARs) that engulf plaques, while another team designed bispecific peptides that ferry amyloid into cells for lysosomal...
Artificial Kinetochores Take the Pressure Off Aging Chromosomes During Meiosis
Researchers at RIKEN have engineered protein‑based artificial kinetochores that compete with natural chromosome kinetochores for microtubule attachment during meiosis. By lowering the overall pulling force, these constructs keep weakened chromosome pairs together in aged mouse oocytes, restoring accurate DNA segregation....
Hawley Unveils Bill to Ban Abortion Pill, Strip FDA Approval
Senator Josh Hawley introduced a bill to immediately withdraw the FDA's safety approval for mifepristone, the primary abortion medication. The legislation follows recent Supreme Court and Trump‑era reviews of the drug and cites a controversial conservative study alleging serious adverse...

AGENT IDE Midterm Results Still Give DCB an Edge for In-Stent Restenosis
Three‑year follow‑up of the AGENT IDE trial shows the Agent paclitaxel‑coated balloon (DCB) outperforms uncoated balloon angioplasty in treating in‑stent restenosis (ISR), with target‑lesion failure (TLF) rates of 32.7% versus 40.9% (hazard ratio 0.72). The advantage is driven mainly by...

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
Foghorn Therapeutics announced a financial update highlighting progress on its lead oncology candidate FHD-909, which remains on schedule in Phase 1 dose‑escalation for SMARCA4‑mutant NSCLC. The company also confirmed that its selective CBP and EP300 degrader programs are slated for...

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
Elutia Inc. reported its Q4 and full‑year 2025 results, highlighting the $88 million sale of its BioEnvelope business to Boston Scientific and a cash position of $36.4 million plus $8 million in escrow. The company submitted a 510(k) for the base biologic matrix...

NanoTess Lands Embecta Deal to Put Its Tech in 14,000 Canadian Pharmacies
Calgary‑based NanoTess has signed a distribution agreement with diabetes‑care company Embecta to place its NanoSALV Catalytic gel in more than 14,000 Canadian pharmacies. NanoSALV, authorized by Health Canada in 2022, uses micron‑scale catalytic particles to speed cellular reactions, reduce inflammation...

FDA Merges Adverse Event Trackers Into One Database
The FDA announced a unified adverse‑event database that will eventually incorporate all of its existing reporting systems, including the vaccine‑side‑effect tracker jointly operated with the CDC. The new platform, called the Adverse Event Monitoring System, centralizes data from drugs, biologics,...
FDA Clears New Large-Bore Catheter for Challenging Stroke Cases
Toro Neurovascular has obtained FDA clearance for its Toro 88 Superbore Catheter, a large‑bore device engineered for challenging stroke interventions. The catheter promises enhanced support, trackability, and stability, addressing the time‑sensitive nature of neurovascular procedures. UCLA interventional neuroradiologist Dr. Satoshi Tateshima...

Pharmaceutical Executive Daily: FDA's New Guidance for Biosimilar Development
The FDA issued its fourth revision of draft biosimilar development guidance, allowing scientifically justified streamlining of pharmacokinetic (PK) studies and estimating up to a 50% cost reduction—about $20 million per program. The new guidance also expands the use of clinical data...
Tailored Training Can Address Biopharma Skills Shortage
Ireland’s National Institute for Bioprocess Research and Training (NIBRT) reports a persistent global shortage of biopharma manufacturing talent, especially engineers skilled in digital bioprocessing, automation and AI. The gap spans cell culture, downstream processing, aseptic manufacturing and quality functions, with...
New Chromatography Resin Developed for Secretory Antibodies
Researchers at BOKU University in Vienna have engineered a novel chromatography resin designed to capture secretory immunoglobulin A (IgA) at titers suitable for commercial manufacturing. The resin employs a reengineered bacterial surface ligand, analogous to Protein A, within a macropore...
Giovanni Traverso
Giovanni Traverso, M.D., Ph.D., is a physician‑scientist who bridges gastroenterology and engineering as an associate member of the Broad Institute, director of the Laboratory for Translational Engineering, MIT associate professor, and Harvard gastroenterologist. His lab creates ingestible electronics, robotic capsules,...
A Better View of How Cells Take Up Mitochondria to Restore Function
Researchers have demonstrated that mesenchymal stromal cells (MSCs) can actively internalize isolated, functional mitochondria through endocytic pathways. The study shows that the internalized organelles retain structural integrity and boost cellular proliferation, stress tolerance, and oxygen consumption. Chemical inhibition of endocytosis...
Trouble Swallowing? A Nanogel Tweak May Keep Therapeutic Stem Cells Alive Longer
Researchers at Kyoto University and McGill University created hybrid stem‑cell spheroids incorporating biodegradable nanogel microfibers. The nanogel‑enhanced spheroids improved oxygen diffusion, increasing cell viability more than fivefold and boosting secretion of regenerative factors. In a rat model of swallowing‑muscle injury,...
Safer Large DNA Insertion Moves Genetic Medicine Toward Scalability
Researchers at Massachusetts General Hospital, in partnership with Full Circles Therapeutics, have introduced a circular single‑stranded DNA donor platform called INSTALL that enables kilobase‑scale gene insertion without triggering the cGAS immune sensor. The method combines a short double‑stranded DNA segment...
Simple 'Cocktail' Of Amino Acids Dramatically Boosts Power of mRNA Therapies and CRISPR Gene Editing
Researchers at Biohub identified a three‑amino‑acid cocktail—methionine, arginine and serine—that dramatically improves lipid nanoparticle (LNP) delivery of therapeutic mRNA and CRISPR components. Co‑administering the supplement boosted protein expression up to 20‑fold and raised gene‑editing rates from roughly 25% to nearly...
Biodegradable Nanoparticles Can Seek and Destroy Diseased Immune Cells
Johns Hopkins researchers have engineered a streamlined biodegradable polymeric nanoparticle that delivers mRNA to T cells, prompting them to generate CD19‑CAR receptors that target disease‑causing B cells. In mice, a single intravenous dose eliminated 95% of circulating B cells within...
A New AI Model Could Help Scientists Design New Forms of Life
Researchers at the Arc Institute unveiled Evo2, an AI model trained on trillions of DNA bases from diverse organisms. By treating DNA as language, Evo2 can generate genome‑scale sequences millions of letters long, demonstrated with Mycoplasma genitalium‑inspired designs. The model...
VIDO – Six Years Later: How VIDO Helped Respond to the COVID-19 Pandemic
VIDO swiftly responded to COVID‑19 by designing a subunit vaccine candidate within days of the SARS‑CoV‑2 genome release, isolating the virus, and establishing animal models that enabled a Phase 1 human trial by early 2021, making it the first Canadian university...
The Gut Microbiome May Influence Brain Aging, Mouse Study Suggests
A University of Pennsylvania study published in Nature shows that gut bacteria from aged mice can impair memory in young mice, effectively accelerating brain aging. The researchers identified the bacterium *Parabacteroides goldsteinii* as the key agent, linking it to inflammation...

Endometriosis Study Aims for Safer Diagnosis
A Worcestershire Acute NHS Trust‑led clinical trial is testing a non‑invasive electrode‑based method to diagnose endometriosis, marking the first such study within the NHS. The technique records small‑intestine muscle activity, which researchers claim shows a pattern unique to patients with...

Engineering Meat: Science Drives Next Agricultural Revolution
For 12,000 years, humanity has produced meat the same way: grow crops, feed animals, convert plants into protein. From a biomanufacturing perspective, it is one of the most complex and least optimized production systems on the planet. What happens when we start...

Phase 2 Trial Compares Dara‑Bor
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/IvK3UNeem9
From Insights to Impact: Rare Disease Therapies with UCB’s Dr. Kim Moran — Episode 246
UCB’s Senior Vice President Dr. Kim Moran discusses the company’s rare disease pipeline, including therapies for mitochondrial TK2 deficiency, on Xtalks Life Science Podcast episode 246. Moran, who pioneered UCB’s Insights‑to‑Impact function, explains how patient‑derived data informs strategy, digital transformation,...

Phase 3
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMx3J8 #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd https://t.co/FLK0sJ0N1w

Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/ikQKjHjscU
Biogen Phase Ib Data Positions Salanersen for SMA Treatment Sequencing
Biogen reported Phase Ib data for its antisense oligonucleotide salanersen, showing substantial neurofilament light chain reductions and new motor milestones in children with spinal muscular atrophy (SMA) who had previously received onasemnogene abeparvovec. The study of 24 participants demonstrated a roughly...

Phase 3 Trial Tests
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/FoT3i0xGcL

Mapping Genomic Alterations in Multiple Myeloma Precursors
Genomic landscape of multiple myeloma and its precursor conditions [May 21, 2025] Jean-Baptiste Alberge et al. @IrenemGhobrial @NatureGenet https://t.co/DDWGRrpI4Y #mmsm #PrecisionMedicine #cagenome https://t.co/LY1MzFXSBN
Lonza Expands Agreement to Manufacture Gene Therapy for Transfusion-Dependent Beta-Thalassemia
Lonza has broadened its agreement with Genetix Biotherapeutics to increase manufacturing capacity for ZYNTEGLO, the sole FDA‑approved gene therapy for transfusion‑dependent beta‑thalassemia. Production will continue at Lonza’s Houston, Texas, dedicated cell‑and‑gene therapy site, with provisions to scale up for future...

Multiple Myeloma Evades GPRC5D T‑Cell Engagers via Multim
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma [Jan 15, 2026] @hollyleeYJ et al. @NBahlis @NatureMedicine https://t.co/mz393mPMAq #mmsm #PrecisionMedicine #tcellrx THREAD: https://t.co/lNX9b7LsnR HT @AuclairDan https://t.co/2qih7LwP1c

First In‑Utero Stem Cell Surgery Cures Spina Bifida
In a First, Researchers Use Stem Cells and Surgery to Treat Spina Bifida in the Womb by @ShellyFan https://t.co/4xO4I0iLJL https://t.co/HV1CGzlMXU
Seven Ways to Skin KRAS: Emerging Approaches to Watch Out For
The article surveys seven early‑stage programmes tackling KRAS, each proposing a distinct therapeutic angle. While many firms still chase the classic model of deeper, longer, or more selective pathway blockade, these initiatives span elegant biochemical tricks to counterintuitive concepts that...

Sequencing Hematologic Cancers Reveals Germline Variant Candidates
Identifying potential germline variants from sequencing hematopoietic malignancies [Dec 4, 2020] Ira L. Kraft, Lucy A. Godley @ASH_hematology Education Book https://t.co/L09eJ55sNW #geneticcounselors #PrecisionMedicine #hemeonc https://t.co/Ggq8IEzQEa
Regulation Will Push Peptide Market to Clean Providers
Consider this arc: peptides were around in niche communities, GLPs from Pharma then exploded, people realized they could take less or source them elsewhere, regulation enters & now gray & black market are going bye-bye & companies like HIMs &...
The FDA Approves Leucovorin for Rare Genetic Condition and Not for Autism
The U.S. Food and Drug Administration approved leucovorin, a synthetic vitamin B9, solely for cerebral folate deficiency, a rare genetic disorder. Earlier this year, President Trump and HHS Secretary Robert Kennedy Jr. promoted the drug as an autism cure, prompting a surge in...

Day 3 Tackles Extending Healthspan and Achieving Longevity Escape Velocity
The @abundance360 Day 3 is at full force, covering one of the most important topics for humanity: how do we extend human healthspan & achieve LEV. We have a powerful lineup of speakers, including my friend @davidasinclair ! https://t.co/SLfeDlbo5f

Black Stripe Marks Successful Agroinfiltration, Red
More agroinfiltration tests. Black sharpie stripe indicates injecred bloom. Right lobe is positive control. Should turn red in the next 72hrs. https://t.co/2lRTbwAjhq

Inside The Race To Reboot Human Cells - EP 60 Nabiha Saklayen
In this episode, host Ashley Vance talks with Nabiha Saklayen, co‑founder and CEO of Celino, about induced pluripotent stem cells (iPSCs) and their rapid evolution from a Nobel‑winning discovery to emerging therapies. They discuss how iPSCs can be reprogrammed from...

Emerging KRAS Combo Therapies Show Promising Progress
The KRAS niche has been a deluge of new selective and pan/multi inhibitors. Now there are combos to watch out for – we may be making progress. Here are insights on 7 of them: https://t.co/F9HmM8A4ud https://t.co/IqWw6n2m3k

GLP‑1 Drug Linked to Longer Survival in Brain Metastases
Another potential GLP-1 drug benefit seen in people with diabetes and brain metastases for improved survival; a retrospective study that needs further assessment but intriguing https://t.co/nZm3xEYQMH https://t.co/V76S7o1MJb
Alzheimer’s Blood Markers Also Flag Certain Amyloidosis Types
The blood neuromarkers p-tau181 and p-tau217 that can predict and diagnose Alzheimer's disease are also abnormal in certain types of amyloidosis, indicating both some non-specificity and potential help in diagnosis of these conditions https://t.co/jodvMY6TNK

Severe COVID/Flu May Boost Lung Cancer Risk
A causal link between severe Covid or flu and lung cancer risk by impairing immunity and promoting inflammation, as shown in multiple murine models https://t.co/NvE6uIYFZh